Acrivon Therapeutics, Inc.
ACRVAcrivon Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision oncology medicines through its proprietary AP3 proteomics platform.
Table of contents
Earnings
Next report
Aug 12, 2026 (In 2 weeks)Competitors
By market cap
By revenue growth
Profile
Acrivon Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision oncology medicines through its proprietary AP3 proteomics platform. The company utilizes direct protein measurement to match therapies with specific patient populations, bypassing the limitations of traditional genomics-based approaches. Its core value proposition lies in identifying responders for its drug candidates across a broad range of solid tumors that lack identifiable genetic mutations.
Acrivon is a pioneer in phosphoproteomics-based precision medicine, positioning itself as a leader in addressing the 90% of cancers that lack actionable genetic drivers.
Questions, answered.
- What is Acrivon Therapeutics, Inc.'s market cap?
- Acrivon Therapeutics, Inc. (ACRV) has a market capitalization of $66.8M and trades on NASDAQ.
- Who are Acrivon Therapeutics, Inc.'s competitors?
- Acrivon Therapeutics, Inc.'s key competitors include Zentalis Pharmaceuticals, Schrödinger, Bristol Myers Squibb, and others. These companies compete in similar markets and product categories.
- Who does Acrivon Therapeutics, Inc. partner with?
- Acrivon Therapeutics, Inc.'s notable partners include Eli Lilly & Company, Akoya Biosciences, Moffitt Cancer Center, and others.
- What subsidiaries does Acrivon Therapeutics, Inc. have?
- Acrivon Therapeutics, Inc.'s subsidiaries include OncoSignature AB.
- Where is Acrivon Therapeutics, Inc. headquartered?
- Acrivon Therapeutics, Inc. is headquartered in United States of America and employs approximately 61 people. It has been publicly traded since 2022.